Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS-Reference-Cited by-同舟云学术

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Published:2019-02 Issue:2 Volume:30 Page:171-210
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Wu Y.-L.^ORCID,Planchard D.,Lu S.,Sun H.,Yamamoto N.,Kim D.-W.,Tan D.S.W.,Yang J.C.-H.,Azrif M.,Mitsudomi T.,Park K.,Soo R.A.,Chang J.W.C.,Alip A.,Peters S.,Douillard J.-Y.

Funder

CTONG

CSCO

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/2/171/27970247/mdy554.pdf

Reference279 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. The incidence and mortality of lung cancer and their relationship to development in Asia;Pakzad;Transl Lung Cancer Res,2015

3. World Cancer Report. http://www.iarc.fr/en/media-centre/iarcnews/2018/wcr.php (November 2018, date last accessed).

4. IARC. Cancer incidence, mortality and prevalence worldwide GLOBOCAN 2012. http://gco.iarc.fr (September 2018, date last accessed).

5. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

Cited by 228 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil;Cancers;2024-09-03

2. Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study;JTO Clinical and Research Reports;2024-09

3. Uniqueness of lung cancer in Southeast Asia;The Lancet Regional Health - Southeast Asia;2024-08

4. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up;Journal of Thoracic Oncology;2024-08

5. Molecular aspects of BRAF and HER2 in prognosis of periampullary carcinoma;Pancreatology;2024-08